IA
ITRM

Insight Advisors’s Iterum Therapeutics ITRM Stock Holding History

Insight Advisors’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,333
Closed -$28K – 324
2021
Q2 		$28K Sell
2,333
-17,900
-88% -$388K 0.01% 309
2021
Q1 		$373K Buy
+20,233
New +$482K 0.12% 217

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Insight Advisors's ITRM Position: Q3 2021 in Review

Insight Advisors sold out of Iterum Therapeutics (ITRM) in Q3 2021, closing a stake of 2,333 shares — an estimated $28K sold.

Insight Advisors first reported a position in ITRM in Q1 2021 and held it in 2 quarters. The position peaked at $373K in Q1 2021. 42 funds tracked by Wall St. Rank hold ITRM as of Q3 2021.

  • Insight Advisors reported no remaining Iterum Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Insight Advisors sold 2,333 Iterum Therapeutics shares in Q3 2021, an estimated $28K.
  • Insight Advisors first reported a position in Iterum Therapeutics in Q1 2021 and held it in 2 quarters.
  • Insight Advisors's Iterum Therapeutics position peaked at $373K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2021.

Based on Insight Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.